Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Foos

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Clinical Therapeutics|August 25, 2005
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United StatesMichael E Minshall, Stéphane Roze, Andrew J Palmer, et al.
Journal of Medical Economics|January 29, 2015
Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United StatesVolker Foos, Nebibe Varol, Bradley H Curtis, et al.
Current Medical Research and Opinion|April 5, 2007
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UKAndrew J Palmer, William J Valentine, Joshua A Ray, et al.
Pharmacoeconomics|November 6, 2025
External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost EffectivenessChristopher G Fawsitt, Howard Thom, David Aceituno, et al.
Current Medical Research and Opinion|August 25, 2004
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-makingAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Current Medical Research and Opinion|August 25, 2004
Validation of the CORE Diabetes Model against epidemiological and clinical studiesAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Journal of Medical Economics|January 30, 2025
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetesPhil McEwan, Martin Bøg, Mads Faurby, et al.
Advances in Therapy|June 6, 2006
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPHWilliam J Valentine, Andrew J Palmer, Katrina M Erny-Albrecht, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 3, 2023
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United StatesJosh Carlson, Volker Foos, Adam Kasle, et al.
Current Medical Research and Opinion|March 16, 2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesJoshua A Ray, Kristina S Boye, Nicole Yurgin, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Therapeutics|August 25, 2005
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United StatesMichael E Minshall, Stéphane Roze, Andrew J Palmer, et al.
Journal of Medical Economics|January 29, 2015
Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United StatesVolker Foos, Nebibe Varol, Bradley H Curtis, et al.
Current Medical Research and Opinion|April 5, 2007
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UKAndrew J Palmer, William J Valentine, Joshua A Ray, et al.
Pharmacoeconomics|November 6, 2025
External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost EffectivenessChristopher G Fawsitt, Howard Thom, David Aceituno, et al.
Current Medical Research and Opinion|August 25, 2004
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-makingAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Current Medical Research and Opinion|August 25, 2004
Validation of the CORE Diabetes Model against epidemiological and clinical studiesAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Journal of Medical Economics|January 30, 2025
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetesPhil McEwan, Martin Bøg, Mads Faurby, et al.
Advances in Therapy|June 6, 2006
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPHWilliam J Valentine, Andrew J Palmer, Katrina M Erny-Albrecht, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 3, 2023
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United StatesJosh Carlson, Volker Foos, Adam Kasle, et al.
Current Medical Research and Opinion|March 16, 2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesJoshua A Ray, Kristina S Boye, Nicole Yurgin, et al.
Pageof 3